GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that the Company has appointed Julian Gangolli to the Board of Directors effective immediately. This follows the announcement on 19 May 2015 of Mr Gangolli’s appointment to the newly created position of President, North America.

“I am delighted to welcome Julian to the GW board of directors as he brings exceptional operational and leadership experience to the group,” stated GW’s Chairman Dr. Geoffrey Guy. “As we advance our commercial plans for Epidiolex, it is of significant value for the Board to tap into the perspective of such an experienced business leader that has extensive product commercialization experience and a successful track record of launching and growing specialty pharmaceutical products in the U.S.”

Mr. Gangolli was, from 2004 until April 2015, President of the North American Pharmaceutical division of Allergan Inc, with responsibility for a 1,400-person integrated commercial operation with sales exceeding $3.8 billion in 2014. As a Corporate Vice President and member of the Executive Committee, Allergan’s most senior leadership team overseeing worldwide operations, Mr. Gangolli was an integral part of the executive management team that transformed Allergan into one of the leading specialty pharmaceutical companies in the U.S. Prior to Allergan, Mr. Gangolli was Vice President, Sales and Marketing at VIVUS, Inc. where he established from inception a fully functioning commercial operation. Prior to VIVUS, Mr. Gangolli held roles at Syntex Pharmaceuticals, Inc. andOrtho-Cilag Pharmaceuticals Ltd. in the UK. He was raised and educated in the UK and is a U.S. citizen. (Original Source)

Shares of GW Pharmaceuticals closed yesterday at $125.85. GWPH has a 1-year high of $133.98 and a 1-year low of $58.16. The stock’s 50-day moving average is $123.45 and its 200-day moving average is $100.13.

On the ratings front, GW Pharmaceuticals has been the subject of a number of recent research reports. In a report issued on June 29, Piper Jaffray analyst Joshua Schimmer reiterated a Buy rating on GWPH, with a price target of $147, which implies an upside of 16.8% from current levels. Separately, on April 14, Leerink Swann’s Joseph Schwartz reiterated a Buy rating on the stock and has a price target of $120.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Joshua Schimmer and Joseph Schwartz have a total average return of 13.5% and 39.0% respectively. Schimmer has a success rate of 69.0% and is ranked #167 out of 3711 analysts, while Schwartz has a success rate of 72.4% and is ranked #30.

GW Pharmaceuticals PLC is engaged in the research, development and commercialisation of cannabinoid prescription medicines to meet patient needs.